Semaglutide vs Tirzepatide: How GLP-1 Agonists Work
18 April 2025 · 5 min read
Research disclaimer: This article is for informational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are prescription medications — their use outside of a supervised clinical context carries meaningful risks. Consult a qualified healthcare professional.
The GLP-1 Agonist Class
Glucagon-like peptide-1 (GLP-1) receptor agonists are among the most clinically significant therapeutic developments of the past two decades. Originally developed for type 2 diabetes management, they have since demonstrated striking efficacy in obesity treatment — and emerging research suggests roles in cardiovascular protection, liver disease, neurodegeneration, and possibly addiction.
GLP-1 is a naturally occurring peptide hormone secreted by intestinal L-cells in response to food intake. It acts on multiple tissue types:
- Pancreas — stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon
- Brain — acts on hypothalamic centres to reduce appetite and increase satiety
- Stomach — slows gastric emptying, contributing to feelings of fullness
- Heart — direct cardioprotective effects under investigation
GLP-1 receptor agonists are synthetic analogues engineered to mimic and extend these actions. Natural GLP-1 has a plasma half-life of under two minutes; pharmaceutical GLP-1 agonists are modified to resist enzymatic degradation, allowing once-weekly dosing.
Semaglutide: The Established Benchmark
Semaglutide (branded as Ozempic for diabetes, Wegovy for obesity) is a GLP-1 receptor agonist developed by Novo Nordisk. It binds exclusively to the GLP-1 receptor.
Clinical trial data from the STEP programme established semaglutide's efficacy in obesity:
- STEP 1 (2021, n=1,961): 2.4 mg weekly semaglutide produced mean weight loss of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group
- STEP 4: Patients who discontinued semaglutide regained approximately two-thirds of lost weight within a year, confirming that the therapy requires continuation for sustained effect
The SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in people with obesity but without diabetes — a landmark finding suggesting effects beyond weight reduction alone.
Tirzepatide: Dual Agonism
Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) was developed by Eli Lilly and represents a mechanistic evolution. Rather than targeting GLP-1 receptors alone, tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously.
GIP is another incretin hormone that enhances insulin secretion and may have additional effects on adipose tissue. The reasoning behind dual agonism is that targeting both pathways may produce synergistic metabolic effects beyond what GLP-1 stimulation alone achieves.
Clinical trial data from the SURMOUNT programme supports this hypothesis:
- SURMOUNT-1 (2022, n=2,539): At the highest dose (15 mg), tirzepatide produced mean weight loss of 20.9% over 72 weeks — with approximately one-third of participants losing ≥25% of body weight
- SURMOUNT-2 extended these findings to patients with type 2 diabetes
A direct head-to-head comparison — SURMOUNT-5 — compared tirzepatide to semaglutide 2.4 mg. Tirzepatide produced approximately 47% greater weight loss, with a mean reduction of ~20% versus ~14% for semaglutide over 72 weeks.
For a deeper look at how the GIP mechanism works and what this means for next-generation compounds, see our article on retatrutide and triple agonism.
Key Differences Summary
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Peak weight loss (trial) | ~15% | ~21% |
| Approval | FDA, TGA, EU | FDA, EU (TGA expanding) |
| Dosing | Once weekly injection | Once weekly injection |
Side Effects and Tolerability
Both drugs share a similar GI side-effect profile — nausea, vomiting, constipation, and diarrhoea are the most commonly reported adverse effects, typically most pronounced during dose escalation. These are largely attributable to the gastric emptying slowdown and central satiety signalling.
Tirzepatide's GIP component appears to modestly improve tolerability in some analyses, though the clinical significance of this is debated.
More serious but rare adverse effects include pancreatitis risk (class effect), thyroid C-cell tumour risk (observed in rodents, clinical significance unclear), and gallbladder disease associated with rapid weight loss.
A 2024 PubMed Reference
For those wanting to dig into the clinical pharmacology, this review in Nature Reviews Drug Discovery provides excellent mechanistic depth: The GLP-1 receptor agonists: a review of their mechanism of action and cardiovascular effects.
Practical Considerations
Both medications are prescription-only and should be initiated and monitored by a physician. Their supply has been constrained by demand in multiple countries. Compounded versions (including those sourced via research peptide suppliers or compounding pharmacies) have become a point of regulatory concern in several jurisdictions — their purity, concentration accuracy, and safety profile should be scrutinised carefully. For tirzepatide research procurement, RetaLABS is a domestic option with published purity verification.
Summary
Semaglutide and tirzepatide represent the most clinically validated peptide-based therapies currently available. The mechanism difference — single versus dual incretin agonism — translates into measurable differences in efficacy outcomes. Tirzepatide currently leads on weight loss magnitude; semaglutide has a longer safety record and broader cardiovascular data. Both have transformed the treatment landscape for obesity and metabolic disease.